Literature DB >> 10416598

Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis.

S J Engle1, J B Hoying, G P Boivin, I Ormsby, P S Gartside, T Doetschman.   

Abstract

The transforming growth factor beta (TGF-beta) pathway is known to play an important role in both human and urine colon cancer. However, the staging, ligand specificity, and mechanism underlying the tumor suppressive activity of this pathway are unknown. We developed a mouse model for colon cancer that identifies an early role for TGF-beta1 in tumor suppression and implicates TGF-beta2 or TGF-beta3 in the prevention of metastasis. Analysis of the development of colon cancer in TGF-beta1 knockout mice pinpoints the defect to the hyperplasty/adenoma transition and reveals that the mechanism involves an inability to maintain epithelial tissue organization and not a loss of growth control, increased inflammatory activity, or increased genetic instability. These mice provide a unique opportunity to investigate the specific role of TGF-beta1 at this critical transition in the development of colon cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416598

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  79 in total

1.  Non-redundant tumour supressor functions of transforming growth factor beta in breast cancer.

Authors:  M Azhar
Journal:  J Biosci       Date:  2001-03       Impact factor: 1.826

2.  Effect of vitamin E succinate on expression of TGF-beta1, c-Jun and JNK1 in human gastric cancer SGC-7901 cells.

Authors:  K Wu; B H Liu; D Y Zhao; Y Zhao
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

Review 3.  TGF-beta antagonists: why suppress a tumor suppressor?

Authors:  Rosemary J Akhurst
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 4.  TGF-beta, T-cell tolerance and anti-CD3 therapy.

Authors:  Ramireddy Bommireddy; Thomas Doetschman
Journal:  Trends Mol Med       Date:  2004-01       Impact factor: 11.951

Review 5.  The two faces of transforming growth factor beta in carcinogenesis.

Authors:  Anita B Roberts; Lalage M Wakefield
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-14       Impact factor: 11.205

6.  GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes.

Authors:  Jingyao Dai; Jian Gu; Maosheng Huang; Cathy Eng; E Scott Kopetz; Lee M Ellis; Ernest Hawk; Xifeng Wu
Journal:  Carcinogenesis       Date:  2012-04-12       Impact factor: 4.944

7.  Genetic and Chemical Models of Colorectal Cancer in Mice.

Authors:  Mandayam O Nandan; Vincent W Yang
Journal:  Curr Colorectal Cancer Rep       Date:  2010-03-10

Review 8.  Colorectal cancer models for novel drug discovery.

Authors:  Daniel Golovko; Dmitriy Kedrin; Ömer H Yilmaz; Jatin Roper
Journal:  Expert Opin Drug Discov       Date:  2015-08-21       Impact factor: 6.098

9.  TGF beta 1 inhibits Ca2+-calcineurin-mediated activation in thymocytes.

Authors:  Ramireddy Bommireddy; Ilona Ormsby; Moying Yin; Gregory P Boivin; George F Babcock; Thomas Doetschman
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

10.  Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.

Authors:  Binwu Tang; Naomi Yoo; Mary Vu; Mizuko Mamura; Jeong-Seok Nam; Akira Ooshima; Zhijun Du; Pierre-Yves Desprez; Miriam R Anver; Aleksandra M Michalowska; Joanna Shih; W Tony Parks; Lalage M Wakefield
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.